Taking Action on Pull Incentives
Estimating the Return on Investment for Incentivising New Antimicrobials in Sweden
Oct 18, 2024
The Global Policy Research Group (GPRG), in partnership with ARMOR, has released a new report addressing the urgent challenge of Antimicrobial Resistance (AMR). AMR remains a critical global health issue, contributing to 1.27 million deaths annually and associated with an additional 4.95 million deaths worldwide. In Sweden alone, AMR accounts for around 330 deaths each year and is linked to over 1,500 associated deaths.
The report examines Sweden’s role in revitalizing the antimicrobial pipeline through innovative financing models. Building on the success of revenue guarantees to secure access to existing antibiotics, it outlines how expanding this model could incentivize the development of new treatments. Through collaboration with Nordic, European, and global partners, Sweden can help ensure access to effective antimicrobials and play a pivotal role in the global fight against drug-resistant infections.
Key Findings:
Return on Investment (ROI):Â A Swedish contribution to a global pull incentive scheme for developing 18 new antimicrobials over 30 years is projected to:
Save over 170 lives, generate €214 million in benefits, and achieve a 2.1:1 ROI over 10 years.
Save at least 2,700 lives, generate €3.35 billion in benefits, and reach a 10.1:1 ROI over 30 years.
Global Impact:Â Sweden's contribution could help save over 5,900 lives in 10 years and over 113,000 lives over 30 years worldwide, driving innovation and access through a collaborative incentive approach.
Cost and Fair Share: The scheme would require Sweden to invest an estimated €3.8 million per drug annually over 10 years, aligning with its fair share within a G7 and EU-funded pull incentive initiative.
By taking action on pull incentives, Sweden has the opportunity to drive critical progress in the fight against AMR, ensuring that new antimicrobials reach those who need them most.
Read the full report to learn more about how Sweden can lead the way in combating antimicrobial resistance.